 |
|  | Sanctura, Vidaza.(New & Approved) : An article from: Skin & Allergy News $5.95 | |
| PHARMION SELECTS MCKESSON TO DISTRIBUTE VIDAZA. : An article from: Biotech Business $5.95 | |
|
|
|
Clinical Data on Vidaza® in Higher-Risk MDS and AML Patients Presented at 47th Annual Meeting of American Society of Hematology
Researchers Present Data on Survival, Time to AML transformation and Safety BOULDER, Colo., Dec. 11 /PRNewswire-FirstCall/ -- Pharmion Corporation ...
From PR Newswire,
12/11/05
| |
|
|
Clinical Data on Vidaza® in Higher-Risk MDS, AML and Other Hematological Malignancies to be Presented at the American Society of Hematology Annual
BOULDER, Colo., Dec. 8 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from several Vidaza(R) studies will be presented at ...
From PR Newswire,
12/8/05
| |
|
|
Pharmion Confirms Vidaza® European Regulatory Status
BOULDER, Colo., Nov. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation , as previously announced, confirmed that the European regulatory authorities ...
From PR Newswire,
11/17/05
| |
|
|
Medsafe
Byline: J. Singh www.medsafe.gov.nz The World Health Organization (WHO) has popularised the approach that access to medicines relies on four integral ...
From Indian Journal of Pharmacology,
11/1/05
by J. Singh
| |
|
|
Book Review
Byline: N. Ananthakrishnan National workshops on good clinical practices and regulatory requirements for clinical trails in India, Training Manual ...
From Indian Journal of Pharmacology,
11/1/05
by N. Ananthakrishnan
| |
|
|
New drug for bone marrow disease
The FDA has approved the first effective treatment for people with a collection of disorders called myelodysplastic syndrome (MDS), in which bone marrow ...
From FDA Consumer,
7/1/04
by
| |
|
|
Marrow drug gets FDA OK
Marrow drug gets FDA OK Associated Press Monday, May 24, 2004 Washington -- The government has approved sale of the first drug to treat a bone marrow disease that can lead to leukemia.
From Milwaukee Journal Sentinel, The,
5/24/04
| |
|
|
SuperGen withdraws stock offering
DUBLIN -- Pharmaceutical company SuperGen announced Monday that it has withdrawn its planned offering of 9.5 million shares of common stock. The ...
From Oakland Tribune,
2/24/04
by David Morrill,
BUSINESS WRITER
| |
|
Home
A
Hydrocodone